What is Clene Nanomedicine?
Clene Nanomedicine is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate, CNM-Au8, is currently under investigation in multiple clinical trials. These studies encompass amyotrophic lateral sclerosis (ALS), early symptomatic ALS, brain energy metabolites, and remyelination in multiple sclerosis. Additionally, Clene Nanomedicine is developing CNM-AgZn17, a gel polymer suspension for infectious diseases and wound healing, and CNM-ZnAg, an antiviral and antibacterial agent for immune support. The company's focus on CSN therapeutics positions it at the forefront of advanced medical solutions.
How much funding has Clene Nanomedicine raised?
Clene Nanomedicine has raised a total of $140.3M across 7 funding rounds:
Series A
$31.6M
Series B
$17M
Debt
$350K
Series D
$42.5M
Other Financing Round
$40M
Other Financing Round
$7.3M
Stock/Share Issuance
$1.5M
Series A (2015): $31.6M, investors not publicly disclosed
Series B (2016): $17M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $42.5M featuring SymBiosis II
Other Financing Round (2023): $40M backed by Vivo Capital, Acuta Capital Partners, and Symbiosis Group
Other Financing Round (2024): $7.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Key Investors in Clene Nanomedicine
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm based in Palo Alto, California, with a focus on private and public equity, as well as venture capital. They are known for their strategic investments in the healthcare sector.
Acuta Capital Partners
Acuta Capital Partners is a California-based financial investment group specializing in healthcare-related investments. They support companies focused on research and innovation to improve health outcomes.
Symbiosis Group
Symbiosis Group is recognized for its role in providing access to scholarly publications and scientific journals, indicating a potential interest in companies at the forefront of medical research and development.
What's next for Clene Nanomedicine?
The substantial enterprise-level funding and recent strategic investment provide Clene Nanomedicine with the necessary capital to advance its robust pipeline of nanotechnology-based therapeutics. This financial backing is expected to accelerate clinical trial progress, particularly for CNM-Au8 in neurodegenerative diseases and CNM-AgZn17 and CNM-ZnAg in infectious disease and wound healing applications. The company is poised to leverage these resources to achieve key development milestones and potentially bring its innovative treatments to market, reinforcing its position in the competitive pharmaceutical landscape.
See full Clene Nanomedicine company page
